Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

详细信息    查看全文

• 作者：Lisa Kitasato (1)
  Taiki Tojo (1) (2)
  Yuko Hatakeyama (2)
  Ryo Kameda (1)
  Takehiro Hashikata (1)
  Minako Yamaoka-Tojo (1) (3) (4) (5)
  
• 关键词：Atherosclerosis ; Endothelial function ; Cardiovascular disease prevention
• 刊名：Cardiovascular Diabetology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：11
• 期：1
• 全文大小：538KB
• 参考文献：1. Lambert J, Aarsen M, Donker AJ, Stehouwer CD: Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. / Arterioscler Thromb Vasc Biol 1996,16(5):705鈥?11. CrossRef
  2. Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE: Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. / J Am Coll Cardiol 1998,32(1):110鈥?16. CrossRef
  3. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A: Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. / Circulation 2000,101(15):1773鈥?779. CrossRef
  4. Celermajer DS: Reliable endothelial function testing: at our fingertips? / Circulation 2008,117(19):2428鈥?430. CrossRef
  5. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, / et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. / J Am Coll Cardiol 2002,39(2):257鈥?65. CrossRef
  6. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. / Circulation 1995,91(5):1314鈥?319. CrossRef
  7. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr: Kuvin JT, Lerman A: Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. / J Am Coll Cardiol 2004,44(11):2137鈥?141. CrossRef
  8. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ: Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. / Circulation 2008,117(19):2467鈥?474. CrossRef
  9. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P: Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. / J Appl Physiol 2006,101(2):545鈥?48. CrossRef
  10. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas RH, Udelson JE: Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. / Am Heart J 2003,146(1):168鈥?74. CrossRef
  11. Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A, Mahmud FH: Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. / Pediatr Diabetes 2007,8(4):193鈥?98. CrossRef
  12. Borel JC, Tamisier R, Gonzalez-Bermejo J, Baguet JP, Monneret D, Arnol N, Roux-Lombard P, Wuyam B, Levy P, Pepin JL: Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial. / Chest 2012,141(3):692鈥?02. CrossRef
  13. Wakaume K, Yamaoka-Tojo M, Nemoto S, Kameda R, Aiba N, Yoshida Y, Machida Y, Masuda T, Izumi T: Pedometer-based exercise increases physical activity and improves endothelial function in patients at high risk of cardiovascular disease. / Jpn J Cardivasc Dis Prev 2012, 47:13鈥?3.
  14. Kitada S, Otsuka Y, Kokubu N, Kasahara Y, Kataoka Y, Noguchi T, Goto Y, Kimura G, Nonogi H: Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. / Cardiovasc Diabetol 2010, 9:75. CrossRef
  15. Nishimura R, Nakagami T, Sone H, Ohashi Y, Tajima N: Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. / Cardiovasc Diabetol 2011, 10:58. CrossRef
  16. Media centre: / Diabetes. In: Fact sheet No312 (August 2011). Geneva: World Health Organization; 2011.
  17. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. / N Eng J Med 1993,329(14):977鈥?86. CrossRef
  18. Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC Jr, Peterson K, Senior P: The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. / Diabetes Care 2012,35(2):409鈥?14. CrossRef
  19. Wascher TC, Graier WF, Bahadori B, Toplak H: Time course of endothelial dysfunction in diabetes mellitus. / Circulation 1994,90(2):1109鈥?110. CrossRef
  20. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. / N Eng J Med 1988,318(20):1315鈥?321. CrossRef
  21. Feener EP, King GL: Vascular dysfunction in diabetes mellitus. / Lancet 1997,350(Suppl 1):SI9-SI13.
  22. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. / J Clin Invest 1991,87(2):432鈥?38. CrossRef
  23. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. / J Clin Invest 1996,97(1):22鈥?8. CrossRef
  24. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. / J Am Coll Cardiol 1999,34(1):146鈥?54. CrossRef
  25. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino RB, Nathan DM, Wagner EH, Kaplan SH, Greenfield S: Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. / Am J Med 1997,102(1):38鈥?7. CrossRef
  26. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. / Diabetes 1994,43(8):960鈥?67. CrossRef
  27. Syvanne M, Taskinen MR: Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. / Lancet 1997,350(Suppl 1):SI20-SI23.
  28. Nathan DM, Meigs J, Singer DE: The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is 鈥?or is it? / Lancet 1997,350(Suppl 1):SI4-SI9.
  29. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA: The clinical implications of endothelial dysfunction. / J Am Coll Cardiol 2003,42(7):1149鈥?160. CrossRef
  30. Fleenor BS, Marshall KD, Rippe C, Seals DR: Replicative aging induces endothelial to mesenchymal transition in human aortic endothelial cells: potential role of inflammation. / J Vasc Res 2012,49(1):59鈥?4. CrossRef
  31. Li J, Jin C, Cleveland JC Jr, Ao L, Xu D, Fullerton DA, Meng X: Enhanced inflammatory responses to toll-like receptor 2/4 stimulation in type 1 diabetic coronary artery endothelial cells: the effect of insulin. / Cardiovasc Diabetol 2010, 9:90. CrossRef
  32. Hamburg NM, Charbonneau F, Gerhard-Herman M, Ganz P, Creager MA: Comparison of endothelial function in young men and women with a family history of premature coronary artery disease. / Am J Cardiol 2004,94(6):783鈥?85. CrossRef
  33. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. / Circulation 2002,105(13):1567鈥?572. CrossRef
  34. de Jongh RT, Serne EH, RG IJ, de Vries G, Stehouwer CD: Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. / Circulation 2004,109(21):2529鈥?535. CrossRef
  35. Gokce N, Vita JA, McDonnell M, Forse AR, Istfan N, Stoeckl M, Lipinska I, Keaney JF Jr, Apovian CM: Effect of medical and surgical weight loss on endothelial vasomotor function in obese patients. / Am J Cardiol 2005,95(2):266鈥?68. CrossRef
  36. Mitchell GF, Parise H, Vita JA, Larson MG, Warner E, Keaney JF Jr, Keyes MJ, Levy D, Vasan RS, Benjamin EJ: Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. / Hypertension 2004,44(2):134鈥?39. CrossRef
  37. Mitchell GF, Vita JA, Larson MG, Parise H, Keyes MJ, Warner E, Vasan RS, Levy D, Benjamin EJ: Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. / Circulation 2005,112(24):3722鈥?728. CrossRef
  38. Frisbee JC: Vascular adrenergic tone and structural narrowing constrain reactive hyperemia in skeletal muscle of obese Zucker rats. / Am J Physiol Heart Circ Physiol 2006,290(5):H2066-H2074. CrossRef
  39. Frisbee JC: Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. / Am J Physiol Regul Integr Comp Physiol 2005,289(2):R307-R316. CrossRef
  40. Phillips SA, Sylvester FA, Frisbee JC: Oxidant stress and constrictor reactivity impair cerebral artery dilation in obese Zucker rats. / Am J Physiol Regul Integr Comp Physiol 2005,288(2):R522-R530. CrossRef
  41. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM: Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. / BMJ 2001,322(7299):1389鈥?393. Clinical research ed CrossRef
  42. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. / N Eng J Med 1998,339(4):229鈥?34. CrossRef
  43. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). / Lancet 1998,352(9131):837鈥?53. CrossRef
  44. Feinglos MN, Bethel MA: Therapy of type 2 diabetes, cardiovascular death, and the UGDP. / Am Heart J 1999,138(5 Pt 1):S346-S352.
  45. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. / The Funagata Diabetes Study. Diabetes care 1999,22(6):920鈥?24. CrossRef
  46. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J: Postprandial glucose regulation and diabetic complications. / Arch Intern Med 2004,164(19):2090鈥?095. CrossRef
  47. Oizumi T, Daimon M, Jimbu Y, Wada K, Kameda W, Susa S, Yamaguchi H, Ohnuma H, Tominaga M, Kato T: Impaired glucose tolerance is a risk factor for stroke in a Japanese sample鈥搕he Funagata study. / Metabolism: clinical and experimental 2008,57(3):333鈥?38. CrossRef
  48. Ansar S, Koska J, Reaven PD: Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. / Cardiovasc Diabetol 2011, 10:61. CrossRef
  49. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. / Circulation 2002,106(16):2067鈥?072. CrossRef
  50. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. / Diabetes Care 2003,26(5):1589鈥?596. CrossRef
  51. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. / Nature 2001,414(6865):813鈥?20. CrossRef
  52. Plutzky J: Inflammation in atherosclerosis and diabetes mellitus. / Rev Endocr Metab Disord 2004,5(3):255鈥?59. CrossRef
  53. Balkau B: New diagnostic criteria for diabetes and mortality in older adults. / DECODE Study Group. European Diabetes Epidemiology Group. Lancet 1999,353(9146):68鈥?9.
  54. Chu CS, Lee KT, Cheng KH, Lee MY, Kuo HF, Lin TH, Su HM, Voon WC, Sheu SH, Lai WT: Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes. / Cardiovasc Diabetol 2012, 11:21. CrossRef
  55. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C: Meal-generated oxidative stress in type 2 diabetic patients. / Diabetes Care 1998,21(9):1529鈥?533. CrossRef
  56. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. / Circulation 2002,106(10):1211鈥?218. CrossRef
  57. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D: Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. / Diabetes 2004,53(3):701鈥?10. CrossRef
  58. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D: Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. / J Am Coll Cardiol 2002,39(7):1145鈥?150. CrossRef
  59. Mita T, Watada H, Shimizu T, Tamura Y, Sato F, Watanabe T, Choi JB, Hirose T, Tanaka Y, Kawamori R: Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. / Arterioscler Thromb Vasc Biol 2007,27(11):2456鈥?462. CrossRef
  60. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. / Lancet 2005,365(9467):1333鈥?346. CrossRef
  61. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. / Lancet 2002,359(9323):2072鈥?077. CrossRef
  62. O'Keefe JH, Bell DS: Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. / Am J Cardiol 2007,100(5):899鈥?04. CrossRef
  63. Standl E, Schnell O: Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. / Diab Vasc Dis Res 2012. Epub ahead of print
  64. Bramlage P, Binz C, Gitt AK, Krekler M, Plate T, Deeg E, Tschope D: Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. / Cardiovasc Diabetol 2010, 9:53. CrossRef
  65. Kurukulasuriya LR, Sowers JR: Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. / Cardiovasc Diabetol 2010, 9:45. CrossRef
  66. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y: Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. / Diabetes Res Clin Pract 2007,76(2):229鈥?35. CrossRef
  67. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, / et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. / Lancet 2005,366(9493):1279鈥?289. CrossRef
  68. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, / et al.: Pioglitazone for diabetes prevention in impaired glucose tolerance. / N Eng J Med 2011,364(12):1104鈥?115. CrossRef
  69. Goldstein MR, Mascitelli L: Pioglitazone for diabetes prevention. / N Eng J Med 2011,365(2):183. author reply 183鈥?84
  70. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H: Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. / J Biol Chem 2002,277(26):23534鈥?3543. CrossRef
  71. Ramachandran A, Ma RC, Snehalatha C: Diabetes in Asia. / Lancet 2010,375(9712):408鈥?18. CrossRef
  72. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY: Epidemic obesity and type 2 diabetes in Asia. / Lancet 2006,368(9548):1681鈥?688. CrossRef
  73. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F: Novel rapid- and short-acting hypoglycemic agent, a calcium(2鈥塻)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. / J Pharmacol Exp Ther 1994,269(2):489鈥?95.
  74. Mogami H, Shibata H, Nobusawa R, Ohnota H, Satou F, Miyazaki J, Kojima I: Inhibition of ATP-sensitive K鈥?鈥塩hannel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. / Eur J Pharmacol 1994,269(3):293鈥?98. CrossRef
  75. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ: Ionophoretic activity of meglitinide analogues. / Diabetes Res 1994,27(2):61鈥?1. Edinburgh, Scotland)
  76. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. / J Pharmacol Exp Ther 2007,322(1):1鈥?. CrossRef
  77. Kaiser N, Nesher R, Oprescu A, Efendic S, Cerasi E: Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells. / Br J Pharmacol 2005,146(6):872鈥?81. CrossRef
  78. Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S: The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K鈥?鈥塩hannels and insulin secretion: comparison with the sulfonylureas and nateglinide. / Eur J Pharmacol 2001,431(1):119鈥?25. CrossRef
  79. Kikuchi M: Non-SU, insulin secretagogues. / Nihon rinsho 1999,57(3):702鈥?08.
  80. Reimann F, Proks P, Ashcroft FM: Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. / Br J Pharmacol 2001,132(7):1542鈥?548. CrossRef
  81. Mori Y, Ojima K, Fuujimori Y, Aoyagi I, Kusama H, Yamazaki Y, Kojima M, Shibata N, Itoh Y, Tajima N: Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. / Endocrine 2006,29(2):309鈥?15. CrossRef
  82. Toyoda Y, Mizutani K, Miwa I: Increase in hepatic glucose metabolism by mitiglinide calcium dehydrate-induced translocation of glucokinase from the nuclear to the cytoplasm. / Prog Med 2008, 28:1951鈥?958.
  83. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A: Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. / Am J Physiol 2001,281(5):E924鈥?30.
  84. Yokoyama H, Kannno S, Ishimura I, Node K: Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. / Metabolism: clinical and experimental 2007,56(11):1458鈥?463. CrossRef
  85. Assaloni R, Da Ros R, Quagliaro L, Piconi L, Maier A, Zuodar G, Motz E, Ceriello A: Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. / Diabetologia 2005,48(9):1919鈥?924. CrossRef
  86. Konya H, Miuchi M, Konishi K, Nagai E, Ueyama T, Kusunoki Y, Kimura Y, Nakamura Y, Ishikawa T, Inokuchi C, / et al.: Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. / J Int Med Res 2009,37(6):1904鈥?912.
  87. Malaisse WJ: Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. / Treat Endocrinol 2003,2(6):401鈥?14. CrossRef
  88. Odawara M: Nateglinide and mitiglinide. / Nihon rinsho 2003,61(7):1230鈥?237.
  89. Yokoyama H, Inoue T, Node K: Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. / Diabetes Res Clin Pract 2009,83(1):77鈥?2. CrossRef
  90. Thisted H, Johnsen SP, Rungby J: Sulfonylureas and the risk of myocardial infarction. / Metabolism: clinical and experimental 2006,55(5 Suppl 1):S16鈥?9.
  91. Quast U, Stephan D, Bieger S, Russ U: The impact of ATP-sensitive K鈥?鈥塩hannel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. / Diabetes 2004,53(Suppl 3):S156鈥?64. CrossRef
  92. Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH: Variations in tissue selectivity amongst insulin secretagogues: a systematic review. / Diabetes Obes Metab 2012,14(2):130鈥?38. CrossRef
  93. Ogawa K, Ikewaki K, Taniguchi I, Takatsuka H, Mori C, Sasaki H, Okazaki F, Shimizu M, Mochizuki S: Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. / Int Heart J 2007,48(3):337鈥?45. CrossRef
  94. Maruyama I, Tomiyama Y, Maruyama K, Ojima K, Kobayashi K, Kobayashi M, Yamazaki Y, Kojima M, Shibata N: Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. / Eur J Pharmacol 2006,531(1鈥?):194鈥?00. CrossRef
  95. Kato T, Inoue T, Node K: Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. / Cardiovasc Diabetol 2010, 9:12. CrossRef
  96. Yamaoka-Tojo M, Tojo T, Izumi T: Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. / Curr Vasc Pharmacol 2008,6(4):271鈥?81. CrossRef
  97. Yamaoka-Tojo M, Tojo T, Kosugi R, Hatakeyama Y, Yoshida Y, Machida Y, Aoyama N, Masuda T, Izumi T: Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. / Lipids Health Dis 2009, 8:41. CrossRef
  98. Gao X: Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. / J Int Med Res 2009,37(3):812鈥?21.
  99. Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, Yoshimasa Y, Miyazaki S: Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. / Circ J 2012,76(3):712鈥?20. CrossRef
  100. Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y: Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. / Endocr J 2009,56(5):657鈥?64. CrossRef
  101. Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y: Effect of mitiglinide on glycemic control over 52鈥墂eeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. / Endocr J 2009,56(6):739鈥?46. CrossRef
  102. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. / Diabetes 2000,49(12):2142鈥?148. CrossRef
  103. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T: Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. / Diabetes Care 2000,23(5):644鈥?49. CrossRef
  104. Kumashiro N, Yoshihara T, Kanazawa Y, Shimizu T, Watada H, Tanaka Y, Fujitani Y, Kawamori R, Hirose T: Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. / Endocr J 2007,54(1):163鈥?66. CrossRef
  105. Nakano T, Inoue I, Satoh K, Yamazaki M, Awata T, Kurihara S, Goto S, Shinoda Y, Komoda T, Katayama S: Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction. / J Atheroscler Thromb 2009,16(1):63鈥?6. CrossRef
  106. Abe M, Okada K, Soma M: Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. / Curr Drug Metab 2011,12(1):57鈥?9. CrossRef
  107. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K: Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. / Endocr J 2010,57(7):579鈥?86. CrossRef
  108. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K: Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. / Expert Opin Pharmacother 2010, 11:169鈥?76. CrossRef
  109. Tschope D, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, Gitt AK: Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients鈥揳n analysis of the DiaRegis registry. / Cardiovasc Diabetol 2011, 10:66. CrossRef
  
• 作者单位：Lisa Kitasato (1)
  Taiki Tojo (1) (2)
  Yuko Hatakeyama (2)
  Ryo Kameda (1)
  Takehiro Hashikata (1)
  Minako Yamaoka-Tojo (1) (3) (4) (5)
  
  1. Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
  2. Department of Cardioangiology, Kitasato University School of Medicine, Sagamihara, Japan
  3. Special Department of Cardiac Rehabilitation and Preventive Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan
  4. Kitasato University School of Allied Health Sciences, Sagamihara, Japan
  5. Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan
  

文摘

The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients. However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients. These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.